AstraZeneca leukaemia drug trial reports positive results
AstraZeneca
11,276.00p
11:15 23/04/24
AstraZeneca said a phase three trial of its Calquence treatment for chronic lymphocytic leukaemia had shown a “statistically-significant and clinically-meaningful improvement in progression-free survival” compared with a combination regimen.
FTSE 100
8,061.16
11:15 23/04/24
FTSE 350
4,429.43
11:15 23/04/24
FTSE All-Share
4,383.53
11:15 23/04/24
Pharmaceuticals & Biotechnology
21,878.89
11:15 23/04/24
Calquence was compared with the combination of rituximab plus a choice of idelalisib or bendamustine, tAstra said in a statement.
“Importantly, the safety and tolerability of Calquence was consistent with the known profile.”
“Calquence is the first BTK inhibitor to show benefit in a phase III trial as a monotherapy compared to current standard-of-care combinations used in relapsed or refractory chronic lymphocytic leukaemia,” said the company's executive vice-president of research and development oncology José Baselga.